News

Top-line data from the immediate post-vaccination observation period of the trial will be reported in late second quarter of 2015. More than 300 patients from 17 institutions in

With these collaborations, Novartis will now have access to new CRISPR technology platforms for the discovery and development of new medicines. A clustered regularly interspaced short palindromic repeats

The Phase II trial is designed to evaluate the safety, efficacy and tolerability of KD025, the company’s orally bioavailable, potent and highly selective inhibitor of Rho-associated coiled-coiled kinase

Currently, the company is enrolling patients in its randomized, double-blind Phase IIb proof of concept trial designed to compare CVC to placebo in around 250 patients with NASH

In the trial, all healthy volunteers completed the treatment phase and results are scheduled to be released during the first quarter of 2015. The company is developing BL-8040

Asserting that harmonisation would be the only way for market access to make a step improvement, Bergströmexplained that it was in everyone’s interests, not just those of pharmaceutical

While the data from this study showed KB001-A was generally safe and well-tolerated, the primary endpoint of increased time to need for antibiotics for worsening respiratory tract signs

The study is based on the same science that has shown tremendous progress in the treatment of Knee Osteoarthritis (KOA). Both arthroscopy and the use of magnetic resonance

The FDA orphan drug designation coincides with the positive opinion of the European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products (COMP) regarding NiCord as a treatment for